COVID-19：与肽梦公司，默克公司的合作研究：开发用于电晕的新型治疗药物
[东京第十二路透社]-
肽梦（4587.T）：
6月12日，该公司宣布将与美国制药巨头默克公司（MRK.N）合作进行新型冠状病毒感染治疗药物的研发。
肽疗法：
多肽疗法将共同研发
除了当前的新冠状病毒，
对于将来可能出现的所有突变型冠状病毒
效果可以预期。
什么是肽梦：
东京大学的一家生物冒险公司旨在发现和开发非标准的肽疗法。
Article [AMP] | Reuters
https://www.google.co.jp/amp/s/jp.mobile.reuters.com/article/amp/idJPKBN23J0HR
PeptiDream Announces Collaboration with Merck & Co., Inc.,
Kenilworth, N.J., U.S.A. to Develop Candidate COVID-19 Therapies
KANAGAWA, JAPAN – June 12th, 2020 – PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)
today announced that it has entered into a collaboration with Merck & Co. Inc., Kenilworth NJ, USA, (“Merck”), known as MSD outside the United States and Canada, for the discovery and development of novel peptide therapeutics capable of neutralizing both the current SARS-CoV-2 virus (Coronavirus Disease “COVID19”) and potential future Coronavirus (“CoV”) outbreaks.
Under this collaboration, the companies will focus their combined efforts on developing peptide therapeutics that may be effective against multiple coronavirus strains.
The agreement builds on the original research collaboration and license agreement between both companies announced April 29, 2015.
PeptiDream will receive an undisclosed upfront payment, as well as be eligible for payments associated with the achievement of certain preclinical, clinical, as well as royalties on future sales of any products that arise from the collaboration.
“We are excited to announce this partnership focused on the discovery and development of peptide candidates targeting multiple coronaviruses. Our wide-ranging collaboration continues to make exceptional progress and I am confident that together we can make an impact in combatting this global challenge,” said Patrick C. Reid PhD, President & CEO of PeptiDream.
“Our experience has shown that good science and strong collaborations are essential to develop medicines and vaccines, and that is especially true now in a global public health emergency,” said Emma Parmee DPhil, vice president, Discovery Chemistry research,Merck & Co., Inc., Kenilworth, NJ, USA., “We look forward to working with scientists at PeptiDream to identify candidates targeting SARS CoV-2 and other coronaviruses.”
PeptiDream is pursuing a multi-pronged strategy toward identifying peptide candidates targeting different sites/regions of coronaviruses as announced previously on April 30, 2020